[The predictive value of plasma fibronectin concentration on fetal growth retardation and preeclampsia at earlier stage of the third trimester].
OBJECTIVE
To evaluate the predictive value of maternal plasma fibronectin concentration at 24-34 weeks on fetal growth retardation (FGR) and preeclampsia.


METHODS
The maternal plasma fibronectin concentrations were measured by rate nephelometric procedure in the 130 initial normal nulliparous pregnant woman at 24-34 gestational weeks. The outcomes of pregnancies were followed. The predictive values of FN predicting on 3 kinds of outcome of pregnancy with FGR, preeclampsia, or FGR complicated preeclampsia were compared.


RESULTS
(1) In a cohort of 130 initially normal nulliparous pregnant women, 10 cases of FGR, 10 cases of preeclampsia, and 4 cases of FGR complicated with preeclampsia were developed, and 106 cases with no complication. The maternal age, gravidity, sampling gestational ages, delivering gestational ages were not significantly different among the 4 groups (P > 0.05). (2) The plasma fibronectin levels in women with FGR, preeclampsia or FGR complicated preeclampsia [(486.45 +/- 122.69) mg/L, (428.38 +/- 118.71) mg/L and (443.66 +/- 68.13) mg/L, respectively] were significantly higher than that in the control [(284.41 +/- 93.83) mg/ L, P < 0.01]. (3) The areas under ROC of predicting on three outcomes of FGR, preeclampsia, or FGR complicated preeclampsia were 0.893, 0.818 and 0.867 respectively. (4) At the best cut point, the sensitivity, specificity, positive predictive value, negative predictive value and Kappa index of FN level predicting on the outcomes of pregnancy with three groups were 57.14%, 95.69%, 61.54%, 94.87%, 0.545 5 (on FGR); 91.27%, 50.00%, 15.38%, 98.29%, 0.1975 (on preeclampsia) and 42.86%, 91.38%, 37.50%, 92.98%, 0.3221 (on FGR complicated with preeclampsia), respectively.


CONCLUSIONS
The maternal plasma fibronectin may be used as an earlier predictor for screening of FGR and the predictive value of FN on FGR is better than on preeclampsia.
Xiong
G
G
Wuhan Research Institute for Family Planning, Wuhan, China.
Wang
Z
Z
Yu
Q
Q
D019540:Area Under Curve; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D005260:Female; D005317:Fetal Growth Retardation / Q000175:diagnosis*; D005353:Fibronectins / Q000097:blood*; D006801:Humans; D011225:Pre-Eclampsia / Q000175:diagnosis*; D011247:Pregnancy; D011256:Pregnancy Outcome; D011262:Pregnancy Trimester, Second / Q000097:blood; D011263:Pregnancy Trimester, Third / Q000097:blood; D011296:Prenatal Diagnosis / Q000379:methods*; D012680:Sensitivity and Specificity
D015415:Biomarkers; D005353:Fibronectins